NASDAQ:STOK Stoke Therapeutics Q2 2026 Earnings Report $28.99 -0.40 (-1.35%) As of 01:10 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Stoke Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.82Beat/MissN/AOne Year Ago EPSN/AStoke Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$4.89 millionBeat/MissN/AYoY Revenue GrowthN/AStoke Therapeutics Announcement DetailsQuarterQ2 2026Date8/3/2026TimeBefore Market OpensConference Call DateMonday, August 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Stoke Therapeutics Earnings HeadlinesStoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial UpdatesJuly 27 at 7:43 PM | finance.yahoo.comStoke Therapeutics (STOK) Receives a Buy from JefferiesJuly 24, 2026 | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 29 at 1:00 AM | Banyan Hill Publishing (Ad)Stoke Therapeutics Inc.July 21, 2026 | barrons.comStoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last StretchJuly 19, 2026 | seekingalpha.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 16, 2026 | businesswire.comSee More Stoke Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email. Email Address About Stoke TherapeuticsStoke Therapeutics (NASDAQ:STOK), headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins. The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy. In addition to STK-001, Stoke is advancing STK-002, its preclinical candidate for spinocerebellar ataxia type 6 (SCA6), along with other discovery-stage programs targeting genetic diseases characterized by insufficient protein levels. Stoke’s approach aims to address the underlying genetic deficiency rather than solely treating symptoms, positioning its pipeline to potentially benefit a range of patient populations with high unmet medical needs. Since going public on the Nasdaq exchange in early 2020, Stoke Therapeutics has grown its research capabilities and established strategic collaborations to support its development efforts. The company’s leadership team brings together expertise in molecular biology, neurology and clinical development, guiding Stoke’s mission to translate its TANGO platform into transformative therapies. Stoke serves patient communities and clinical partners globally, with ongoing and planned trials conducted across North America and Europe.View Stoke Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Bloom Energy May Be the Most Important AI Infrastructure StockCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to ComeThese 3 Stocks Have Soared in 2026—Can They Keep Climbing?UPS Just Gave Investors a Second Chance to BuyHasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
